Zolpidem-associated hallucinations and serotonin reuptake inhibition: A possible interaction

Journal of Toxicology - Clinical Toxicology

Volumn 36, Issue 3, 1998, Pages 195-203

  Elko, Curtis J ^a   Burgess, Jefferey L ^a   Robertson, William O ^a  

^a Washington Poison Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DESIPRAMINE; FLUOXETINE; LORAZEPAM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; TRAZODONE; VENLAFAXINE; ZOLPIDEM TARTRATE;

ADOLESCENT; ADULT; CASE REPORT; DEPRESSION; FEMALE; HALLUCINATION; HUMAN; MALE; REVIEW; VISUAL HALLUCINATION;

EID: 0031868743     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659809028939     Document Type: Review

References (52)

1. George P, Rossey G, Depoortere H, Mompon B, Allen J, Wick A. Zolpidem and related compounds: Syntheses, physical properties and structure-activity relationships. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:11-24.
2. Budavare S, O'Neil MJ, Smith A, Heckelman PE, Eds. The Merck Index, 11th edition. Whitehouse Station, NJ: Merck & Co., Inc., 1989.
3. RTECS® Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health. Cincinnati, Ohio (CDROM version): Micromedex Inc. Englewood, Colorado, (expiration date: 1/31/98).
4. Langer SZ, Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988; 29:763-766.
5. Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:55-70.
6. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355-372.
7. 1) subtype. J Pharmacol Exp Ther 1988;245:1033-1041.
8. 3H]zolpidem. J Pharmacol Exp Ther 1988;247:309-323.
9. Guidotti A, Berkovich A, Ferrarese C, Santi MR, Costa E. Neuronal-glial differential processing of DBI to yield ligands to central or peripheral benzodiazepine recognition sites. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:25-38.
10. A receptors in acutely dissociated rat striatal and cerebellar neurons. Neuropharmacology 1996;35: 137-145.
11. 1-receptor selective imidazopyridine hypnotic zolpidem. Pharmacol Biochem Behav 1988;29:781-783.
12. Sieghart W. Heterogeneity of benzodiazepine receptors. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:39-45.
13. Lheureux P, Debailleul G, De Witte O, Askenasi R. Zolpidem intoxication mimicking narcotic overdose: Response to flumazenil. Hum Exp Toxicol 1990;9: 105-107.
14. Patat A, Naef MM, van Gessel E, Forster A, Dubruc C, Rosenzweig P. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994;56:430-436.
15. McKernan RM, Wafford K, Quirk K, et al. The pharmacology of the benzodiazepine site of the GABA-A receptor is dependent on the type of γ-subunit present. J Recept Signal Transduct Res 1995;15:173-183.
16. 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 1990;54: 1802-1804.
17. Scatton B, Claustre Y, Dennis T, Nishikawa T. Zolpidem, a novel nonbenzodiazepine hypnotic. II. Effects on cerebellar cyclic GMP levels and cerebral monoamines. J Pharmacol Exp Ther 1986;237: 659-665.
18. Bartholini G. Growing aspects of hypnotic drugs. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:1-9.
19. Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986;237:649-658.
20. Gaillard JM, Kafi-de St-Hilaire S, Blois R. Pharmacological considerations on sleep mechanisms. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:71-80.
21. Sanger DJ, Joly D, Zivkovic B. The behavioral pharmacology of zolpidem: Comparisons with other compounds acting at the benzodiazepine receptor. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:111-121.
22. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313: 35-42.
23. Zivkovic B, Perrault G, Morel E, Sanger DJ. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:87-108.
24. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: A randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996;19:333-340.
25. Palminteri R, Narbonne G. Safety profile of zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:351-361.
26. Scharf MB, Kaffeman M, Rodgers L, Segal J. Single dose tolerance study of zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:175-181.
27. Abadie P, Rioux P, Scatton B, et al. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 1996;295:35-44.
28. Byrnes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone. Brain Res Bull 1992;29:905-908.
29. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-1255.
30. Gillin JC, Buchsbaum MS, Valladares-Neto DC, et al. Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: A positron emission tomography study. Neuropsychopharmacology 1996;15:302-313.
31. Piercey MF, Hoffmann WE, Cooper M. The hypnotics triazolam and zolpidem have identical metabolic effects throughout the brain: Implications for benzodiazepine receptor subtypes. Brain Res 1991;554: 244-252.
32. Rush CR, Griffiths RR. Zolpidem, triazolam and temazepam: Behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996; 16:146-157.
33. Schmid L, Bottlaender M, Fuseau C, Fournier D, Brouillet E, Maziére M. Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. J Neurochem 1995;65: 1880-1886.
34. Ganzoni E, Santoni JP, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: A 3-year post-marketing surveillance study in Switzerland. J Int Med Res 1995;23:61-73.
35. Gamier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud AE, Efthymiou ML. Acute zolpidem poisoning - analysis of 344 cases. J Toxicol Clin Toxicol 1994;32:391-404.
36. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice. J Int Med Res 1992;20:162-170.
37. Scharf MB, Roth T, Vogel G, Walsh JK. A multi-center, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199.
38. Ansseau M, Pitchot W, Hansenne M, Gonzales-Moreno A. Psychotic reactions to zolpidem. Lancet 1992;339:809.
39. Iruela LM, Ibañez-Rojo V, Baca E. Zolpidem-induced macropsia in anorexic woman. Lancet 1993; 342:443-444.
40. Iruela LM, Ibañez-Rojo V, Baca E. More on zolpidem side-effects. Lancet 1993;342:1495-1496.
41. Katz SE. Possible paroxetine-zolpidem interaction. Lancet 1995;152:1689.
42. Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry 1996;8:89-91.
43. Markowitz JS, Rames LJ, Reeves N, Thomas SG. Zolpidem and hallucinations. Ann Emerg Med 1997; 29:300-301.
44. Morselli PL. Zolpidem side-effects. Lancet 1993; 342:868-869.
45. Pies RW. Dose-related sensory distortions with zolpidem. J Clin Psychiatry 1995;56:35-36.
46. van Puijenbroek EP, Egberts AC, Krom HJ. Visual hallucinations and amnesia associated with the use of zolpidem. Int J Clin Pharmacol Ther 1996;34:318.
47. Kurta DL, Myers LB, Krenzelok EP. Zolpidem (Ambien): A pediatric case series. J Toxicol Clin Toxicol 1997;35:453-457.
48. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Clin Pharmacokinet 1995:29;142-153.
49. Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, Allard S. The effect of co-administration of zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996;34:178-183.
50. Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology 1988;96:63-66.
51. Harvengt C, Hulhoven R, Desager JP, et al. Drug interactions investigated with zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Sauvanet JP, Langer SZ, Morselli PL, eds., New York: Raven Press Ltd., 1988:165-173.
52. Hulhoven R, Desager JP, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Ther 1988;8:471-476.